SecBot SecBot
Biotech Drug Report Generated Oct 29, 2026

ROTATEQ

MRK·Merck & Co., Inc.
MIXED
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already marketed since 2006; no further approval steps needed.
Why 4/10
RotaTeq is an already-approved, marketed vaccine with no pending PDUFA or pivotal readout. The defining binary events (FDA approval in 2006, CDC schedule change in January 2026) are past. As a mature product within Merck's $66B+ revenue base, even a material sales decline would not be a binary stock-moving event. Per the rubric, an approved drug with no pending regulatory decision scores 3-5; RotaTeq lands at 4.
Actionable Insight MIXED

RotaTeq has no upcoming binary regulatory catalysts. The key metric to track is the trajectory of Merck's vaccine segment sales in quarterly earnings reports, which will reveal how quickly the January 2026 CDC recommendation downgrade is eroding RotaTeq utilization. Investors should also watch for any policy reversals or changes to the childhood immunization schedule under the current administration.

Price Chart

Loading chart...

Executive Summary

RotaTeq is Merck's oral rotavirus vaccine, approved by the FDA in 2006 and administered to infants in a three-dose series to prevent severe rotavirus gastroenteritis. It generated $711 million in worldwide sales in 2024, making it a modest contributor to Merck's $65B+ annual revenue. The vaccine faces a significant commercial headwind after the CDC in January 2026 downgraded rotavirus vaccination from a routine recommendation to shared clinical decision-making, which Bernstein analysts estimated could cost Merck up to $2 billion annually across affected vaccines. RotaTeq competes with GSK's Rotarix and other global vaccines. As a mature, approved product within a diversified pharma giant, RotaTeq has no upcoming binary catalysts and is unlikely to drive a major share-price move on its own.

How It Works

RotaTeq is a liquid oral vaccine given to infants. It contains five weakened live rotavirus strains that replicate in the small intestine, training the immune system to recognize and fight real rotavirus infection. Rotavirus causes severe diarrhea, vomiting, fever, and dehydration in young children. The vaccine is given as a three-dose series starting at 2 months of age.

Trial Status

RotaTeq was approved by the FDA in February 2006 and has been on the market for over 20 years. It is a standard pediatric vaccine in the U.S. and many other countries. Two FDA supplement approvals were issued in 2026 (March 13 and May 15), relating to labeling or manufacturing updates.

The Two-Sided Case

▲ Bull Case4
RotaTeq is a well-established, FDA-approved vaccine with over 20 years of real-world use and a strong safety/efficacy profile.
The global rotavirus vaccine market is projected to grow from ~$5.6B in 2026 to ~$12.9B by 2034 (CAGR 11%), per Fortune Business Insights, providing long-term growth runway.
RotaTeq is the only rotavirus vaccine indicated to protect against the G2 strain, a potential differentiation vs. GSK's Rotarix.
Merck's Q3 2026 earnings (reported Oct 29, 2026) showed total vaccines sales growing, with Gardasil up 14% and overall pharmaceutical sales up 4%.
▼ Bear Case5
In January 2026, the CDC downgraded rotavirus vaccination from a routine universal recommendation to shared clinical decision-making, which is expected to reduce uptake significantly.
Bernstein analysts estimated Merck could face a potential $2 billion annual revenue hit from the CDC schedule changes, with RotaTeq as a major exposure.
RotaTeq generated only $711 million in worldwide sales in 2024, making it a small fraction of Merck's $65B+ total revenue, limiting its impact on the stock.
RotaTeq faces competition from GSK's Rotarix (RV1) and lower-cost vaccines from Serum Institute of India and Bharat Biotech in global markets.
The CDC recommendation change could accelerate a shift toward GSK's 2-dose Rotarix regimen over Merck's 3-dose RotaTeq schedule.

Upcoming Catalysts

  • No upcoming binary catalysts for RotaTeq specifically. The key ongoing event to watch is the commercial impact of the January 2026 CDC recommendation downgrade from routine vaccination to shared clinical decision-making, which will show up in Merck's quarterly vaccine sales reports.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Merck & Co., Inc. 8-K MRK ·Originating report

Sources · 13

Hover a chip for the title
1 fda.gov2 reuters.com3 biospace.com4 cdc.gov5 fda.gov6 fda.gov7 usnews.com8 fortunebusinessinsights.com9 druganalyst.com10 businesswire.com11 sec.gov12 fda.gov13 jamanetwork.com